Literature DB >> 4817854

Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition.

M Sandler, R D Johnson, C R Ruthven, J L Reid, D B Calne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4817854     DOI： 10.1038/247364b0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  8 in total

1.  Gout induced by L-dopa and decarboxylase inhibitors.

Authors:  D B Calne; J Fermaglich
Journal:  Postgrad Med J       Date:  1976-04       Impact factor: 2.401

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 3.  Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

4.  In vivo effects of new inhibitors of catechol-O-methyl transferase.

Authors:  E Rivas; M L de Ceballos; O Nieto; J A Fontenla
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

Review 5.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Chronic L-DOPA treatment of mice: a behavioural and biochemical study.

Authors:  R Bailey; E Crisp; D M Jackson; O Jenkins
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

7.  The effect of carbidopa and benserazide on human plasma 5-hydroxytryptophan levels.

Authors:  S N Young; S Gauthier; G Chouinard; G M Anderson; W C Purdy
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

8.  Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.

Authors:  Frank Schneider; Lavi Erisson; Hooman Beygi; Margaret Bradbury; Orit Cohen-Barak; Igor D Grachev; Serge Guzy; Pippa S Loupe; Micha Levi; Mirna McDonald; Juha-Matti Savola; Spyros Papapetropoulos; William G Tracewell; Maria Velinova; Ofer Spiegelstein
Journal:  Br J Clin Pharmacol       Date:  2018-08-09       Impact factor: 4.335
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.